Ophthalmic pharmaceuticals and medical technology company Glaukos Corporation (NYSE:GKOS) announced on Thursday the commercial availability of Epioxa HD / Epioxa, a topical therapy for the treatment of keratoconus, a rare, sight-threatening corneal disease.

The product is now available for ordering directly from Glaukos or through its specialty pharmaceutical distribution network.

Epioxa is positioned as the first and only FDA-approved, incision-free topical drug therapy for keratoconus, representing a shift in corneal cross-linking treatment. The therapy is catalysed by enriched oxygen and light, and is designed to reduce procedural pain associated with epithelium removal, streamline treatment, and support recovery while delivering clinically meaningful outcomes.

Following the launch, Glaukos plans to increase investment in patient awareness, education, and access initiatives to address underdiagnosis and undertreatment. These efforts include patient access support programmes, a patient access liaison team, co-pay assistance, uninsured patient support, and awareness campaigns aimed at earlier detection and diagnosis.